Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, held virtually February 25-26, 2026.
Management, including CEO Ben Zeskind and CSO Brett Hall, will give a company presentation and hold 1x1 investor meetings on Thursday, February 26, 2026 at 10:00 am ET. The presentation will be webcast live and archived in the company’s Investor Relations Events & Presentations section.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
IMRX’s 3.85% gain comes with mixed peer moves: RCKT +1.22%, ASMB +4.23%, FULC +1.43% versus TECX -4.35% and LRMR -3.81%, pointing to stock-specific dynamics rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Clinical data update | Positive | +24.0% | Reported strong Phase 2a survival and response data in first-line pancreatic cancer. |
| Dec 23 | Data event preview | Positive | +8.1% | Announced upcoming webcast to present 12‑month overall survival data for Phase 2a trial. |
| Dec 17 | Phase 3 planning | Positive | -4.2% | Secured FDA and EMA alignment for global Phase 3 MAPKeeper 301 registrational trial. |
| Dec 16 | Index inclusion | Positive | -0.7% | Announced upcoming addition to the Nasdaq Biotechnology Index (NBI). |
| Nov 25 | Investor conference | Neutral | -0.7% | Disclosed participation in the Piper Sandler 37th Annual Healthcare Conference. |
Recent clinically focused and index-related catalysts often produced positive reactions, though regulatory/strategic updates have occasionally seen muted or negative price moves.
Over the past few months, IMRX highlighted key progress for atebimetinib, including strong Phase 2a pancreatic cancer survival data on Jan 7, 2026 that drew a +23.96% move, and regulatory alignment for the Phase 3 MAPKeeper 301 trial on Dec 17, 2025. The company also gained inclusion in the Nasdaq Biotechnology Index and regularly presents at investor conferences. Today’s conference update continues this pattern of active investor engagement alongside advancing late-stage development.
Regulatory & Risk Context
An effective Form S-3 on Aug 13, 2025 registered up to $300,000,000 of securities, including an equity distribution agreement prospectus supplement for up to $100,000,000 of Class A stock within that total, giving the company flexibility to raise capital via registered offerings.
Market Pulse Summary
This announcement highlights IMRX management’s participation in the Oppenheimer conference on Feb 25–26, 2026, continuing a pattern of active investor outreach similar to prior conference appearances. It offers another forum to discuss the late-stage atebimetinib program and business strategy following recent positive Phase 2a data. With an effective $300,000,000 shelf and recent insider option grants and open‑market purchases, investors may watch for future updates on trial progress and financing plans.
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company’s pipeline, platform, and business strategy.
Format: Company Presentation and 1x1 Investor Meetings
Date/Time: Thursday, February 26, 2026, at 10:00 am ET
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. Atebimetinib is currently planned to be evaluated in a Phase 3 trial in first-line pancreatic cancer, which is expected to begin dosing in mid-2026. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Gina Nugent
Gina.nugent.external@immuneering.com
Investor Contact:
Courtney Dugan
Cdugan@immuneering.com
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When will Immuneering (IMRX) present at the Oppenheimer Healthcare Life Sciences Conference in 2026?
Who from Immuneering (IMRX) will speak at the February 26, 2026 presentation?
How can investors watch Immuneering's (IMRX) Oppenheimer conference presentation?
What topics will Immuneering (IMRX) cover at the Oppenheimer conference on February 26, 2026?
Will Immuneering (IMRX) offer investor meetings at the Oppenheimer 36th Annual conference?
